AI giant Anthropic is aggressively expanding its footprint in the life sciences, reportedly acquiring stealth startup Coefficient Bio in a deal valued at $400 million. The stock-based transaction, first reported by The Information and TechCrunch, comes as Anthropic pivots toward high-value specialized sectors like drug discovery.
New York-based Coefficient Bio, led by former Evozyne executive Aris Theologis and Biogen scientist Nathan Frey, specializes in using AI to streamline biological research. This acquisition follows the recent launch of "Claude for Life Sciences," signaling Anthropic’s intent to lead in what Eric Kauderer-Abrams, Anthropic’s head of biology, calls one of the company's "largest strategic bets."
The massive investment arrives at a complicated time for the AI firm. While Anthropic is scaling its healthcare capabilities, it is simultaneously navigating a federal crackdown; the Department of Health and Human Services (HHS) recently restricted the use of Claude tools within the agency. By acquiring Coefficient, Anthropic appears to be shoring up its private-sector biotech muscle even as its government-sector access faces headwinds.
